Amarin Corporation (AMRN) revenue breakdown

Healthcare · Drug Manufacturers - General · Market cap $245M

By product, Product Revenue, Net is the largest at 86% of fiscal 2025 revenue; Licensing and Royalty Revenue grew fastest, 45% a year over 9 years.

Revenue by product

Fiscal years, as Amarin Corporation reports them in its 10-K filings; fiscal 2025 total $214M.

Products2016201720182019202020212022202320242025Share
Product Revenue, Net$129M$180M$228M$427M$607M$580M$367M$285M$205M$183M 86%
Licensing and Royalty Revenue$1M$1M$843,000$2M$7M$3M$3M$22M$24M$31M 14%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMRN.
Open AMRN in Investingly

Questions

Where does Amarin Corporation make its money?

In fiscal 2025, by product: Product Revenue, Net $183M, Licensing and Royalty Revenue $31M.

From Amarin Corporation's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.